- Established market leader in stroke AI imaging receives its
first FDA clearance in the lung imaging space.
- With this expanded foundation of AI-driven healthcare
solutions, the Oxford-based
company remains committed to driving innovation and delivering
impactful advancements in imaging biomarkers.
OXFORD,
England, and CHICAGO, May 17, 2024
/PRNewswire/ -- Brainomix, a pioneer in artificial intelligence
(AI) imaging solutions to enable precision medicine, is proud to
announce the FDA clearance of its latest product, Brainomix 360
e-Lung. Brainomix's entry into the lung imaging space follows a
series of successful clearances and widespread clinical adoption of
its Brainomix 360 Stroke platform in both the US and Europe.
The clearance of e-Lung marks a significant milestone in
Brainomix's journey to expand its footprint in medical imaging
beyond stroke-related applications and represents a notable step
forward in the quest for advanced lung imaging solutions. The
company, with its rich academic heritage and record of scientific
excellence, will expand its research collaborations in the
pulmonology space to yield new insights to inform future iterations
of e-Lung and chart a path towards continual improvements for the
lung imaging technology.
Dr Deji Adegunsoye,
Assistant Professor of Medicine and Scientific Director of the
Interstitial Lung Disease Program at University of Chicago Medicine, said: "This is an
exciting step for Brainomix, who have a demonstrated track record
of developing novel AI-based solutions in stroke and are now
applying that expertise to develop innovative tools in the lung
space. The preliminary data for e-Lung is impressive and would
indicate that we have a promising tool that could help to expedite
healthcare delivery and improve clinically meaningful outcomes
for patients with lung disease."
Brainomix recently announced the publication of a new
study1 in the prestigious peer-reviewed journal
American Journal of Respiratory and Critical Care Medicine
(AJRCCM), resulting from a research collaboration with AstraZeneca.
The results showed that Brainomix's proprietary lung imaging
biomarkers, which include the weighted reticulovascular score
(WRVS), stratified patients at risk of Idiopathic Pulmonary
Fibrosis (IPF) progression, outperforming standard measures.
Dr Michalis Papadakis, CEO
and Co-Founder of Brainomix, said: "We are harnessing our expertise
in AI-powered imaging to develop novel biomarkers in other disease
indications where AI can support imaging-based diagnostic and
treatment decisions.
"This e-Lung FDA clearance reflects our focus on developing
innovative solutions that empower healthcare professionals with
cutting-edge tools for sophisticated disease evaluation, enhancing
access to treatments that can ultimately work to improve patient
outcomes."
Brainomix will be presenting its latest e-Lung data at the
American Thoracic Society (ATS) annual conference in San Diego May
17th – 22nd, including results from
research collaborations with Heidelberg University and with
Seattle-based Avalyn Pharma.
- Am. J. Respir. Crit. Care Med.: 2024 Feb 16 - e-Lung CT
Biomarker Stratifies Patients at Risk of IPF Progression in a
52-Week Clinical Trial
https://www.atsjournals.org/doi/abs/10.1164/rccm.202312-2274LE
About Brainomix
Brainomix specializes in the creation of AI-powered software
solutions to enable precision medicine for better treatment
decisions in stroke and lung fibrosis. With origins as a spin-out
from the University of Oxford, Brainomix is an expanding
commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries.
A private company, backed by leading healthtech investors,
Brainomix has innovated award-winning imaging biomarkers and
software solutions that have been clinically adopted in hundreds of
hospitals worldwide. Its first product, the Brainomix 360 stroke
platform, provides clinicians with the most comprehensive stroke
imaging solution, driving increased treatment rates and improving
functional independence for patients.
To learn more about Brainomix and its technology
visit www.brainomix.com, and follow us
on Twitter, LinkedIn and Facebook.
Contacts
Jeff Wyrtzen, Chief Marketing
& Business Development Officer
jwyrtzen@brainomix.com
M +44 (0)7927 164210
T +44 (0)1865 582730
Media enquiries
Charles Consultants
Sue Charles
Sue@charles-consultants.com
M +44 (0)7968 726585
Logo -
https://mma.prnewswire.com/media/1989193/3856380/Brainomix_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/brainomix-achieves-breakthrough-with-fda-clearance-of-e-lung-ai-software-302144832.html
SOURCE Brainomix